MOTS-c Peptide Guide: Mitochondrial Function, Insulin Sensitivity & Dosing (2026)
For educational purposes only. This content is not medical advice and does not diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any peptide protocol.
MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA Type-c) is a mitochondrial-derived peptide (MDP) consisting of 16 amino acids, encoded by the mitochondrial genome. Discovered in 2015 by Dr. Changhan David Lee's laboratory at the University of Southern California, MOTS-c represents a paradigm shift in our understanding of how mitochondria communicate with the rest of the cell and the body.
MOTS-c is the first peptide demonstrated to be encoded by mitochondrial DNA and to function as a systemic signaling molecule. It acts as a metabolic regulator, influencing insulin sensitivity, fat metabolism, exercise adaptation, and cellular stress resistance — making it one of the most promising peptides in the longevity and metabolic optimization space.
Citation-ready: MOTS-c is a mitochondrial-derived peptide that regulates metabolic homeostasis by activating AMPK signaling, improving insulin sensitivity, and promoting exercise-like metabolic adaptations. Published in Cell Metabolism (2015), its discovery established mitochondrial DNA as an active source of systemic regulatory peptides.
Explore the full MOTS-c compound profile in the DoseCraft Library.
The Science of Mitochondrial-Derived Peptides
What Are Mitochondrial-Derived Peptides?
Mitochondria — the energy-producing organelles in every cell — contain their own small genome (mtDNA). For decades, mtDNA was thought to encode only 13 proteins involved in the electron transport chain. The discovery of MOTS-c (and other MDPs like humanin and SHLP peptides) revealed that mtDNA also encodes small signaling peptides that regulate metabolism, stress response, and aging throughout the body.
This discovery means mitochondria are not just passive energy factories — they are active signaling centers that communicate with the nucleus and other cells.
Where MOTS-c Fits in the MDP Family
| Peptide | Length | Key Function | Discovery |
|---|---|---|---|
| MOTS-c | 16 amino acids | Metabolic regulation, insulin sensitivity | 2015 |
| Humanin | 24 amino acids | Cytoprotection, anti-apoptosis | 2001 |
| SHLP1-6 | 24-38 amino acids | Various protective functions | 2016 |
MOTS-c is unique among MDPs for its demonstrated effects on whole-body metabolism and its exercise-mimetic properties.
MOTS-c Mechanism of Action
1. AMPK Activation (Evidence Tier: Clinical)
MOTS-c activates AMP-activated protein kinase (AMPK), often called the "metabolic master switch." AMPK activation triggers:
- Increased fatty acid oxidation (fat burning)
- Enhanced glucose uptake (independent of insulin)
- Mitochondrial biogenesis (creation of new mitochondria)
- Autophagy upregulation (cellular cleanup)
- Inhibition of mTOR (reducing excessive growth signaling)
AMPK activation is the same pathway triggered by exercise, caloric restriction, and the drug metformin. MOTS-c achieves similar metabolic signaling through an endogenous peptide pathway.
2. Insulin Sensitivity Enhancement (Evidence Tier: Clinical)
MOTS-c improves insulin sensitivity through multiple mechanisms:
- Direct enhancement of cellular glucose uptake
- Reduction of insulin resistance in skeletal muscle
- Improvement of glucose tolerance in diet-induced obesity models
- Modulation of the folate-methionine cycle affecting cellular metabolism
In mouse models, MOTS-c administration prevented diet-induced obesity and insulin resistance even when animals were fed a high-fat diet.
Citation-ready: In preclinical studies, MOTS-c administration prevented high-fat diet-induced insulin resistance and obesity in mice through AMPK-dependent pathways, demonstrating effects comparable to exercise and caloric restriction on metabolic parameters.
3. Exercise Mimetic Properties (Evidence Tier: Clinical)
MOTS-c has been described as an "exercise mimetic" because it activates many of the same metabolic pathways as physical exercise:
| Exercise Effect | MOTS-c Equivalent | Mechanism |
|---|---|---|
| Fat oxidation increase | Yes | AMPK activation |
| Glucose uptake increase | Yes | AMPK + independent pathways |
| Mitochondrial biogenesis | Yes | PGC-1alpha signaling |
| Inflammatory reduction | Yes | NF-kB modulation |
| Endurance improvement | Yes (in animal models) | Metabolic efficiency |
Important: MOTS-c is not a replacement for exercise. It shares molecular pathways with exercise but does not replicate the full spectrum of physical training benefits (mechanical loading, cardiovascular conditioning, neuromuscular adaptation). Leading practitioners position MOTS-c as an adjunct to — not a substitute for — regular physical activity.
4. Cellular Stress Resistance (Evidence Tier: Clinical)
MOTS-c enhances cellular resilience through:
- Nuclear translocation during stress (MOTS-c physically moves to the nucleus)
- Interaction with stress-responsive transcription factors
- Upregulation of antioxidant defense genes
- Protection against metabolic stress and mitochondrial dysfunction
This stress-adaptive property makes MOTS-c relevant not just for metabolism but for general cellular resilience and longevity.
5. Age-Related Decline (Evidence Tier: Clinical)
Circulating MOTS-c levels decline significantly with age:
| Age Group | Relative MOTS-c Level |
|---|---|
| Young adults (20-30) | High (baseline) |
| Middle-aged (40-50) | Moderate (declining) |
| Elderly (60-70) | Low (significantly reduced) |
| Very elderly (80+) | Very low |
This age-related decline parallels the metabolic deterioration associated with aging — suggesting that restoring MOTS-c levels may counteract age-related metabolic dysfunction.
MOTS-c Dosage Protocol
Standard Dosing
| Parameter | Recommendation | Evidence Tier |
|---|---|---|
| Dose per injection | 5-10 mg | Expert |
| Frequency | 3-5x per week | Expert |
| Cycle length | 4-8 weeks | Expert |
| Rest period | 4 weeks | Expert |
Protocol Options
Protocol A: Conservative
| Parameter | Value |
|---|---|
| Dose | 5 mg |
| Frequency | 3x per week (M/W/F) |
| Duration | 4 weeks |
| Rest | 4 weeks |
| Total per cycle | 60 mg |
Protocol B: Standard
| Parameter | Value |
|---|---|
| Dose | 10 mg |
| Frequency | 3x per week (M/W/F) |
| Duration | 4-6 weeks |
| Rest | 4 weeks |
| Total per cycle | 120-180 mg |
Protocol C: Intensive
| Parameter | Value |
|---|---|
| Dose | 10 mg |
| Frequency | 5x per week (M-F) |
| Duration | 4 weeks |
| Rest | 4 weeks |
| Total per cycle | 200 mg |
Most clinical experts recommend Protocol B as the standard starting point for metabolic optimization.
Weight-Based Consideration
Some practitioners use weight-based dosing, though flat dosing is more common:
| Body Weight | Conservative | Standard |
|---|---|---|
| 60 kg | 5 mg | 7.5 mg |
| 80 kg | 5 mg | 10 mg |
| 100 kg | 7.5 mg | 10 mg |
Use the DoseCraft Calculator for reconstitution math and syringe volumes.
How to Administer MOTS-c
Step 1: Reconstitute
MOTS-c typically comes in 5 mg or 10 mg vials.
For a 10 mg vial with 1 mL BAC water:
- Concentration = 10,000 mcg/mL (10 mg/mL)
- 5 mg dose = 0.5 mL = 50 units
- 10 mg dose = 1.0 mL = 100 units (full syringe)
For a 10 mg vial with 0.5 mL BAC water:
- Concentration = 20 mg/mL
- 5 mg dose = 0.25 mL = 25 units
- 10 mg dose = 0.5 mL = 50 units
Step 2: Injection Site
Subcutaneous injection in the lower abdomen. MOTS-c acts systemically, so injection site is not critical for targeting specific tissues.
Step 3: Timing
Some practitioners recommend morning administration to align with natural metabolic rhythms and AMPK cycling. Others administer pre-exercise to potentially enhance the metabolic effects of training. No published data definitively supports one timing over another.
Step 4: Storage
- Lyophilized: Refrigerated or room temperature (stable)
- Reconstituted: Refrigerate, use within 28 days
- MOTS-c is relatively stable compared to some peptides
MOTS-c for Specific Goals
Metabolic Optimization
MOTS-c's primary application is metabolic health:
- Insulin sensitivity: Improved glucose handling, reduced fasting insulin
- Body composition: Enhanced fat oxidation, reduced visceral fat
- Energy metabolism: Improved mitochondrial function and efficiency
- Blood lipids: Potential improvements in triglycerides and cholesterol ratios
Biomarkers to monitor: Fasting glucose, fasting insulin, HOMA-IR, HbA1c, triglycerides, body composition (DEXA scan)
Longevity Protocol
MOTS-c addresses one of the nine hallmarks of aging — mitochondrial dysfunction:
| Hallmark of Aging | MOTS-c Relevance |
|---|---|
| Mitochondrial dysfunction | Direct — enhances mitochondrial function and biogenesis |
| Deregulated nutrient sensing | Direct — modulates AMPK/mTOR axis |
| Cellular senescence | Indirect — may delay senescence via stress resistance |
| Loss of proteostasis | Indirect — autophagy promotion |
| Altered intercellular communication | Direct — systemic metabolic signaling |
Exercise Enhancement
As an exercise mimetic, MOTS-c may enhance training adaptations:
- Pre-workout administration (30-60 minutes before exercise)
- May enhance AMPK-mediated exercise adaptations
- Could improve endurance capacity (demonstrated in animal models)
- Not a substitute for training, but potentially a training amplifier
Evidence tier: Experimental (animal data for exercise enhancement, human metabolic data)
MOTS-c Stacking Options
MOTS-c + Epitalon (Comprehensive Longevity Stack)
| Compound | Dose | Frequency | Target |
|---|---|---|---|
| MOTS-c | 10 mg | 3-5x weekly | Mitochondrial aging |
| Epitalon | 5-10 mg | Daily x 10-20 days | Telomere aging |
Why it works: MOTS-c optimizes mitochondrial function (energy aging) while Epitalon maintains telomere length (chromosomal aging). These are two of the nine hallmarks of aging, addressed through completely independent mechanisms.
MOTS-c + GHK-Cu (Metabolic Longevity Stack)
| Compound | Dose | Frequency | Target |
|---|---|---|---|
| MOTS-c | 10 mg | 3-5x weekly | Metabolic optimization |
| GHK-Cu | 400-600 mcg | Daily | Gene expression, tissue repair |
Why it works: MOTS-c addresses metabolic dysfunction while GHK-Cu resets gene expression toward youthful patterns. Combined, they target metabolic, genetic, and structural aging.
MOTS-c + BPC-157 (Recovery Stack)
| Compound | Dose | Frequency | Target |
|---|---|---|---|
| MOTS-c | 5-10 mg | 3x weekly | Metabolic support, exercise recovery |
| BPC-157 | 250-500 mcg | 2x daily | Tissue repair, inflammation |
Why it works: For athletes or active individuals, MOTS-c enhances metabolic adaptation to training while BPC-157 accelerates tissue recovery.
Explore all stacking options in the DoseCraft Stacking Guide.
MOTS-c Research: Published Evidence
Key Studies
| Study | Year | Finding | Significance |
|---|---|---|---|
| Lee et al., Cell Metabolism | 2015 | Discovery of MOTS-c as mitochondrial-derived peptide | Paradigm-shifting: mtDNA encodes signaling peptides |
| Lee et al., Cell Metabolism | 2015 | MOTS-c prevents diet-induced obesity and insulin resistance | Metabolic protection without diet change |
| Kim et al., Cell Metabolism | 2018 | MOTS-c translocates to nucleus during stress | Established MOTS-c as nuclear gene regulator |
| Reynolds et al., Aging Cell | 2020 | MOTS-c levels decline with age | Explained age-related metabolic decline |
| D'Souza et al., Aging Cell | 2023 | MOTS-c improves physical capacity in aged mice | Functional improvement in aging |
Current Research Directions
- Human clinical trials for metabolic syndrome
- MOTS-c in exercise science and sports medicine
- Neuroprotective applications
- Cancer metabolism interactions
- Combination with other longevity interventions
MOTS-c Safety Profile
Reported Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Injection site reaction | Common | Mild |
| Transient warmth/flushing | Occasional | Mild |
| Mild GI discomfort | Rare | Mild |
| Hypoglycemia-like symptoms | Rare (more likely if combined with glucose-lowering agents) | Moderate |
Safety Considerations
- Diabetes medications: MOTS-c improves insulin sensitivity. Combining with metformin, insulin, or sulfonylureas could cause hypoglycemia. Monitor blood glucose closely and inform your healthcare provider.
- Cancer: MOTS-c modulates metabolic pathways involved in cancer cell metabolism. Research is ongoing. Consult an oncologist before use if you have a cancer history.
- Pregnancy/breastfeeding: No safety data. Avoid.
- Fasting protocols: MOTS-c activates AMPK, similar to fasting. Combining MOTS-c with extended fasting could theoretically amplify metabolic effects. Use caution and monitor how you feel.
Measuring MOTS-c Effectiveness
Objective Biomarkers
| Biomarker | Baseline Test | Follow-Up | Expected Change |
|---|---|---|---|
| Fasting glucose | Before cycle | Week 4, Week 8 | Decrease |
| Fasting insulin | Before cycle | Week 4, Week 8 | Decrease |
| HOMA-IR | Calculated | Calculated | Decrease |
| HbA1c | Before cycle | 3 months | Decrease |
| Triglycerides | Before cycle | Week 4, Week 8 | Decrease |
| Body fat % | Before cycle | Monthly | Decrease |
| VO2max (if testing) | Before cycle | After cycle | Increase |
Subjective Markers
- Energy levels throughout the day
- Exercise endurance and recovery
- Appetite regulation
- Body composition changes (visual and measurement)
- Cognitive clarity and focus
Track all biomarkers and subjective outcomes in the DoseCraft Protocol Builder.
MOTS-c Cost Analysis
| Protocol | Dose/Frequency | Duration | Total Needed | Estimated Cost |
|---|---|---|---|---|
| Conservative | 5 mg 3x/week | 4 weeks | 60 mg | $120-240 |
| Standard | 10 mg 3x/week | 6 weeks | 180 mg | $360-720 |
| Intensive | 10 mg 5x/week | 4 weeks | 200 mg | $400-800 |
| Annual (3 cycles standard) | 10 mg 3x/week | 18 weeks total | 540 mg | $1,080-2,160 |
MOTS-c is one of the more expensive peptides per cycle due to its higher milligram dosing. Cost-efficiency improves with larger vial purchases.
Frequently Asked Questions
What is MOTS-c peptide?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded by mitochondrial DNA. Discovered in 2015, it functions as a systemic metabolic regulator that activates AMPK, improves insulin sensitivity, enhances fat oxidation, and promotes mitochondrial biogenesis. It is sometimes called an "exercise mimetic" because it activates many of the same metabolic pathways as physical exercise.
How does MOTS-c improve metabolism?
MOTS-c activates AMPK (AMP-activated protein kinase), the master metabolic switch that controls fatty acid oxidation, glucose uptake, mitochondrial biogenesis, and autophagy. By activating AMPK, MOTS-c shifts cellular metabolism toward fat burning, improved glucose handling, and enhanced energy efficiency — effects similar to exercise and caloric restriction.
What is the recommended MOTS-c dosage?
The standard MOTS-c protocol is 5-10 mg per injection, 3-5 times per week, for 4-8 weeks, followed by a 4-week rest period. Most practitioners recommend starting with 5 mg three times weekly and increasing to 10 mg based on response and tolerance.
Can MOTS-c replace exercise?
No. MOTS-c shares some molecular pathways with exercise but does not replicate the full benefits of physical training — including mechanical loading for bone/muscle, cardiovascular conditioning, neuromuscular adaptation, and psychological benefits. Leading practitioners position MOTS-c as a complement to exercise, not a replacement. It may enhance the metabolic adaptations from training.
Is MOTS-c the same as metformin?
MOTS-c and metformin both activate AMPK and improve insulin sensitivity, but they work through different upstream mechanisms. MOTS-c is an endogenous peptide that the body naturally produces, while metformin is a synthetic drug. Their metabolic effects overlap but are not identical. Combining MOTS-c with metformin could amplify glucose-lowering effects, so blood sugar monitoring is essential.
How long before MOTS-c shows results?
Metabolic biomarker changes (fasting glucose, insulin) may be detectable within 2-4 weeks. Subjective energy improvements are often reported within the first 1-2 weeks. Body composition changes typically require 4-8 weeks. Full assessment requires completing at least one cycle with before and after bloodwork.
Can I stack MOTS-c with other peptides?
Yes. MOTS-c stacks well with Epitalon (complementary longevity pathways), GHK-Cu (metabolic + gene expression optimization), and BPC-157 (metabolic support + tissue repair). Its unique AMPK-mediated mechanism does not overlap with most other peptide pathways.
Why do MOTS-c levels decline with age?
MOTS-c levels decline with age due to reduced mitochondrial function and altered mitochondrial gene expression. This decline parallels the metabolic deterioration associated with aging — including reduced insulin sensitivity, decreased fat oxidation, and lower energy levels. Supplementing with MOTS-c may help restore youthful metabolic signaling.
Build Your MOTS-c Protocol
Configure your metabolic optimization protocol with the DoseCraft Protocol Builder. View the complete MOTS-c compound profile, use the Calculator for reconstitution, and explore longevity stacks in the Stacking Guide.
For educational purposes only. This content has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before beginning any peptide protocol.